Plasmodium falciparum parasites with PfATP4 drug resistance mutation Gly223Arg
PfATP4-targeting antimalarials, such as the spironindolone cipargamin (CIP), are known to successfully kill human-infecting Plasmodium falciparum parasites. However, the Gly223Arg (G223R) mutation in the binding cavity of PfATP4, appearing both in field isolates and selected in lab settings via continuous CIP exposure, results in resistance to the lethal effects of CIP treatment. To date, there is no known blood-stage P. falciparum line that contains a CRISPR-Cas9 mediated G223R mutation. Here, we provide the whole genome sequencing (WGS) data for a PSS knockdown-Dd2G223R line used to interrogate whether CIP resistance could be reverted to CIP susceptibility with a tandem reduction in phosphatidylserine (PS) production via knock-down of phosphatidylserine synthase (PSS) expression.